The following table sets forth the computation of basic and diluted net loss per common share attributable to common stockholders (in thousands, except share and per share data):


	Three Months Ended March 31,
	2026		2025
Numerator:
Net loss	$	(17,465)	$	(22,017)
Denominator:
Weighted average shares used to compute basic and diluted net loss per share	61,824,843		52,488,199
Net loss per common share—basic and diluted	$	(0.28)	$	(0.42)

The weighted average number of shares used to compute basic and diluted net loss per share excludes unvested early exercised common stock options subject to repurchase.

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:


	March 31,
	2026	2025
Options to purchase common stock	1,666,074	1,741,440
Public and private common stock warrants	3,277,155	5,235,409
Restricted Stock Units	3,557,390	5,426,805
Shares issued to Stereolabs employees and subject to vesting	660,005	—
Share purchase rights under the ESPP	267,175	549,260
Unvested RSAs	—	388,626

Total	9,427,799	13,341,540